Table 1 Demographics, disease characteristics, and treatment at ultrasound examination
From: Ultrasonographic assessment reveals detailed distribution of synovial inflammation in Blau syndrome
Patient number | NOD2 mutation | Age (months) | Duration of treatment at ultrasound examination (months) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Â | Â | At ultrasound examination | At onset of joint symptom | At onset of skin lesion | At diagnosis of uveitis | NSAID | Corticosteroid | Methotrexate | TNF antagonist |
1†| R334W | 10 | NA | 6 | NA | NA | NA | NA | NA |
2†ref[34] | R334W | 66 | 19 | 6 | NA | NA | NA | 13 | NA |
3 ref[36] | D382E | 111 | NA | NA | 88 | NA | NA | 60 | 11 (infliximab) |
4 | R587C | 115 | 53 | NA | NA | NA | NA | 32 | 32 (etanercept) |
5 | R334W | 146* | 24 | 7 | 39 | NA | NA | NA | NA |
154** | NA | NA | 3 | 3 (infliximab) | |||||
6 | R334W | 153* | 29 | 21 | 35 | 12 | 112 | 124 | NA |
166** | NA | NA | 137 | 12 (infliximab) | |||||
7 ref[6] | R334Q | 160 | 52 | NA | NA | 105 | NA | 60 | 44 (infliximab) |
8 ref[6] | R334W | 212 | 24 | 8 | 48 | 188 | 142 | 184 | NA |
9 ref[6] | R334Q | 294 | 34 | 24 | 60 | 270 | 259 | 135 | 45 (infliximab) |
10†ref[3] | R334W | 452 | NR‡ | 24 | 156 | NA | NA | NA | NA |